Debunk the Junk: 4 Common Myths About Insulin Pumps
Starting on an insulin pump can feel like a big step, especially for someone who’s been managing their diabetes a certain way for years. But with the right support, it can also be an empowering transition.
As clinicians, we each bring our own experiences and perspectives when it comes to diabetes technology. And often, our patients surprise us in wonderful ways. That’s why it’s helpful to pause and reflect on the assumptions we may carry about who’s “right” for pump therapy.
Let’s explore a few common myths I hear in practice. By unpacking these together, we can make more personalized, informed decisions and help each person find the tools that fit their life and goals.
Insulin Pumps Are Only for Type 1 Diabetes
One of the most common misconceptions I hear about insulin pump therapy is that it’s only for people with type 1 diabetes. And for a long time, that was true.
In fact, the first FDA-approved automated insulin delivery system for type 2 diabetes wasn’t approved until August 2024, less than a year ago.
Of course, many clinicians have been prescribing pumps off-label for years, especially in cases where insulin needs resemble those of type 1 (such as in type 3c diabetes), or when there are barriers to managing multiple daily injections.
The truth is, anyone who requires daily insulin, regardless of their specific diagnosis, should be evaluated as a potential candidate for insulin pump therapy. There are many benefits to continuous insulin infusion, including reducing the burden of multiple daily injections and improving quality of life.
Diabetes Needs to be "Under Control" First
Over the years, I’ve worked with many clients who were told by previous healthcare providers that they needed to “get their diabetes under control” before they could even be considered for an insulin pump.
In fact, I’ve worked in clinical settings where pump start protocols required an A1c below 9.0% before initiating therapy.
But today, insulin pump therapy is increasingly being recognized as a solution for individuals with elevated A1c levels or “uncontrolled” diabetes. If someone’s A1c has remained high despite using multiple daily injections, it’s a signal that their current regimen may not be working, and it’s time to try something new.
Many patients experience improved glucose stability after starting on a pump, especially with the support of automated insulin delivery systems. An A1c value or diagnosis timeline shouldn’t be a barrier to considering pump therapy.
Expert Carbohydrate-Counting is a Must
As a nutrition professional, I can say with confidence: expert carbohydrate counting is a myth. It’s the white whale of diabetes perfectionism, nearly impossible to achieve consistently, and the expectation often sets our patients up for frustration and failure.
At best, it’s carb estimating. And that doesn’t even take into account the glycemic impact of other factors like protein, saturated fat, caffeine, alcohol, or hydration status.
Newer AID systems, like the iLet from Beta Bionics and Twiist from Sequel, aren’t even asking for carb counts anymore. They rely on simplified meal announcements or even emojis (how Gen-Z!).
Not only is expert carb counting no longer necessary, it’s becoming increasingly irrelevant. Don’t let carb counting be a barrier to insulin pump therapy.
Automated Means “Set It and Forget It”
While automated insulin delivery (AID) systems represent a major tech advancement, and for many, a life-changing improvement in diabetes management, we’re still a long way from a fully closed-loop, “artificial pancreas” solution.
Insulin pumps still require daily attention and active participation. This includes tasks like refilling cartridges or reservoirs, changing infusion sites or pods, and entering mealtime announcements.
It’s important to set realistic expectations about pump therapy before getting started. Diabetes Care and Education Specialists are uniquely trained and qualified to guide supportive, informed conversations about what to expect, and how to partner effectively with individuals throughout the transition.
Key Takeaways
Insulin pumps aren’t just for people with type 1 diabetes. People with any type requiring insulin may benefit from pump therapy.
Our patients don’t need “perfect” diabetes control to get started. For many, pump therapy is part of the solution to improving glucose stability, not a reward for achieving it.
Expert carb counting is no longer a requirement. New AID systems are making pump therapy more accessible, even for those who struggle with traditional carb counting.
Automation doesn’t mean autopilot. Today’s insulin pumps still require engagement, teamwork, and guidance from a knowledgeable care team.
The bottom line? Insulin pump therapy isn’t one-size-fits-all, but it may be more accessible, adaptable, and empowering than many people think.
- Commissioner O of the. Fda clears first device to enable automated insulin dosing for individuals with type 2 diabetes. FDA. https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes. Published August 27, 2024. Accessed July 18, 2025.
- Chatziravdeli V, Lambrou GI, Samartzi A, et al. A Systematic Review and Meta-Analysis of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Type-2 Diabetes. Medicina (Kaunas). 2023;59(1):141. Published 2023 Jan 10. doi:10.3390/medicina59010141
- Mehta SN, Tinsley LJ, Kruger D, et al. Improved glycemic control following transition to tubeless insulin pump therapy in adults with type 1 diabetes. Clinical Diabetes. 2021;39(1):72-79. doi:10.2337/cd20-0022
- Anandhakrishnan A, Hussain S. Automating insulin delivery through pump and continuous glucose monitoring connectivity: Maximizing opportunities to improve outcomes. Diabetes Obesity Metabolism. 2024;26(S7):27-46. doi:10.1111/dom.15920
- Greenwood DA, Howell F, Scher L, et al. A framework for optimizing technology-enabled diabetes and cardiometabolic care and education: the role of the diabetes care and education specialist. Diabetes Educ. 2020;46(4):315-322. doi:10.1177/0145721720935125
Discover more from Sarah Hormachea
Subscribe to get the latest posts sent to your email.
